ReviewFrontiers in cell and developmental biology2026
Advances in Traditional Chinese Medicine for chronic obstructive pulmonary disease through multi-omics approaches.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- From Yufeining to Kaempferol: Multi-Target Anti-Inflammatory, Antioxidant, and Anti-Apoptotic Mechanisms Targeting the STAT3-TP53-IL1B Signaling Network in COPD Therapy.Molecules (Basel, Switzerland) · 2026Article
- Mitochondrial dysfunction and the regulatory cell death crosstalk network in chronic obstructive pulmonary disease: from oxidative stress mechanisms to targeted therapeutic strategies.Frontiers in immunology · 2026Review
- UHPLC -Q-Orbitrap HRMS Integrated with Network Pharmacology Reveals the Anti-COPD Mechanism of Jianzhong Peiyuan Decoction and Functional Validation of Core Component Luteolin.Journal of inflammation research · 2026Article
- Epitranscriptomics, immunometabolism, and NETosis: unlocking novel mechanisms of traditional Chinese medicine in COPD.Frontiers in immunology · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is a common and complex heterogeneous chronic inflammatory airway disorder characterized by multifactorial pathogenesis and limited therapeutic options. It remains one of the leading causes of morbidity and mortality worldwide, severely impairing patients' quality of life and life expectancy. Traditional Chinese Medicine (TCM), with its holistic perspective, syndrome differentiation, and multi-component formulations, is widely used in the adjunctive treatment and rehabilitation of COPD. Evidence suggests that TCM can relieve symptoms, reduce acute exacerbations, and enhance quality of life. However, the "multi-component-multi-target-multi-pathway" nature of TCM formulas has long made their mechanisms difficult to systematically elucidate. In recent years, the rapid development of high-throughput multi-omics technologies has provided unprecedented opportunities to decipher the systems biology mechanisms underlying TCM treatment of COPD. Multi-dimensional data from network pharmacology, genomics, transcriptomics, proteomics, metabolomics, and microbiomics can comprehensively reveal disease-related molecular changes. These findings provide scientific evidence for the objectification of TCM syndromes, the identification of biomarkers, and the clarification of multi-target mechanisms in key herbal formulas, such as Bufei Jianpi granules. Moreover, multi-omics studies have also promoted exploration of emerging fields such as the "lung-gut axis", providing new theoretical perspectives for understanding the complex pathological processes of COPD. This review systematically summarizes recent advances in TCM-based prevention and treatment of COPD using multi-omics strategies. Key progress includes the application of network pharmacology and pharmacogenomics in component-target prediction, the role of transcriptomics/proteomics in molecular target validation, and the value of metabolomics and microbiomics in uncovering metabolic reprogramming and lung-gut axis regulation. Integrated multi-omics approaches also demonstrate significant potential in biomarker discovery and the development of precision TCM. In addition, this review provides a critical evaluation of current trends, potential breakthroughs, challenges, and opportunities in advancing TCM from empirical medicine toward evidence-based and precision medicine, aiming to offer systematic and comprehensive theoretical foundations and research perspectives for TCM-based COPD therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.